Wuxi Biologics (2269.HK) 23H1 - The Positives, the Negatives and the Outlook
There're highlights in WuXi Bio’s interim report, making us look forward to its full-year result. But WuXi Bio faces challenges in order...
442 Views
ECM Weekly (20th August 2023) - Indigo, Vinfast, SBFC, Concord, Wuxi, NSDL, LianLian, Fedbank
Aequitas Research puts out a weekly update on the deals that were covered by the team recently along with updates for upcoming IPOs.
382 Views
WuXi XDC Cayman Pre-IPO - The Negatives - Bottlenecks Have Held Margins Back. Receivables Ballooning
WuXi XDC Cayman Inc (1877628D HK) is looking to raise at least US$100m in its upcoming Hong Kong IPO. In this note, we will talk about the not-so...
536 Views
WuXi XDC Cayman Pre-IPO - The Positives - Sales Have Surged Leading to Market Share Gains
WuXi XDC Cayman Inc (1877628D HK) is looking to raise at least US$100m in its upcoming Hong Kong IPO. In this note, we will talk about the positive...
462 Views
Porton Pharma Solutions (300363.CH) 23H1 - Performance Pressure Would Remain in 2023
Porton's weak performance will continue in 23H2. As a latecomer, its ADC CDMO business is still at early stage. When the entire sector is at bottom...
305 Views